Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Evommune, Inc.NYSE: EVMN
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows 15.4% year over year
Q1 FY2026 free cash flow of $27.59M (cash outflow) rose 15.4% year over year. Sequentially, it rose 64.2% from the prior quarter.
Context
- Free cash flow amounted to 589.8% of revenue in FY2025, down 242.8 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (76.68M) USD
- Year-over-year change
- -31.6%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (76.68M) | -31.6% |
| FY2024 | 2024-12-31 | (58.28M) | -93.7% |
| FY2023 | 2023-12-31 | (30.09M) | — |
Free Cash Flow vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 free cash flow of $80.36M is the 5th largest of the 10 companies compared; the peer median is $53.49M.
- Free cash flow amounts to 803.6% of revenue for EVMN, versus a peer median of 42.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $271.54M | +79.5% | +53.6% | 3565.9% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $150.6M | +246.1% | +46.1% | 5.6% |
| LTM Jun 2026 | $131.37M | +229.2% | -25.8% | 45.2% | |
| LTM Sep 2026 | $112.33M | +69.7% | — | 42.2% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $80.36M | — | — | 803.6% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $80.18M | +31.6% | +11.6% | — |
| LTM Mar 2026 | $59.11M | -51.8% | -20.4% | 39.1% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $53.49M | +83.3% | +13.4% | — |
| LTM Mar 2026 | $26.02M | -34.4% | +21.3% | 90.0% | |
| LTM Mar 2026 | $22.12M | -63.0% | — | 28.3% | |
| Peer median (excluding EVMN) | $53.49M | +69.7% | +13.4% | 42.2% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 3.34M | 7.42M | (4.12M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 125K | 6.51M | (837K) |
| Other Working Capital | 3.22M | 918K | (3.28M) |
| Other Non-Cash Items | (261K) | (98K) | (4.84M) |
| Operating Cash Flow | (29.97M) | (58.2M) | (76.44M) |
| Capital Expenditures | (118K) | (88K) | (235K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (91.31M) | (90.26M) | (199.17M) |
| Sales of Investments | 43M | 86.35M | 84.1M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (48.43M) | (3.99M) | (115.31M) |
| Debt Repayment | 0 | 0 | (373K) |
| Common Stock Issued | 63.98M | 49.84M | 222.36M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (230K) | (423K) | (1.22M) |
| Financing Cash Flow | 63.75M | 49.42M | 220.76M |
| Effect of Forex Changes | 43.67M | (1) | (1.21M) |
| Net Change in Cash | 29.02M | (12.77M) | 27.81M |
| Free Cash Flow | (30.09M) | (58.28M) | (76.68M) |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.